• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $7,563 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-20 Mln

Viking Therapeutics Inc. (VKTX) Share Price

$68.62

As on 12-Apr-2024 16:09 EDT

up-down-arrow $-2.25-3.17%

  • Prev Close info

    $70.87

  • Day's Openinfo

    $70.00

  • Today's Highinfo

    $70.81

  • Today's Lowinfo

    $68.42

  • Today's Volumeinfo

    2,722,710

  • 52 Week rangeinfo

    $8.28 - 99.41

Please wait...

Viking Therapeutics Inc. (VKTX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Viking Therapeutics (VKTX)
268.73 8.17 226.30 287.90 126.31 47.08 --
S&P BSE Sensex
2.77 1.01 3.52 23.42 14.40 13.97 12.62
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 12-Apr-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Viking Therapeutics (VKTX)
97.98 104.35 -18.29 -29.80 4.84 87.77 241.18
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Viking Therapeutics Inc. (VKTX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Viking Therapeutics Inc. (VKTX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Viking Therapeutics Inc. (VKTX)

        President, CEO & Director

        Dr. Brian Lian Ph.D.

        Chief Financial Officer

        Mr. Gregory S. Zante

        Headquarters

        San Diego, CA

        FAQs for Viking Therapeutics Inc. (VKTX)

        The total asset value of Viking Therapeutics Inc. (VKTX) stood at $ 368 Mln as on 31-Dec-23

        The share price of Viking Therapeutics Inc. (VKTX) is $68.62 (NASDAQ) as of 12-Apr-2024 16:09 EDT. Viking Therapeutics Inc. (VKTX) has given a return of 126.31% in the last 3 years.

        Viking Therapeutics Inc. (VKTX) has a market capitalisation of $ 7,563 Mln as on 12-Apr-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Viking Therapeutics Inc. (VKTX) is 21.71 times as on 12-Apr-2024, a 5.94% premium to its peers’ median range of 3.13 times.

        Since, TTM earnings of Viking Therapeutics Inc. (VKTX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Viking Therapeutics Inc. (VKTX) and enter the required number of quantities and click on buy to purchase the shares of Viking Therapeutics Inc. (VKTX).

        Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

        The CEO & director of Dr. Brian Lian Ph.D.. is Viking Therapeutics Inc. (VKTX), and CFO & Sr. VP is Mr. Gregory S. Zante.

        The promoters of Viking Therapeutics Inc. (VKTX) have pledged 0% of the total equity as on Dec-23.

        Viking Therapeutics Inc. (VKTX) Ratios
        Return on equity(%)
        -34.79
        Return on capital employed(%)
        -34.6
        Debt-to-equity ratio
        0
        Dividend yield(%)
        --

        No, TTM profit after tax of Viking Therapeutics Inc. (VKTX) was $-20 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $7,563.16 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-19.53 Mln
        • Cash date-information $362.08 Mln
        • Total Debt info $1.26 Mln
        • Insider's Holding 5.49%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $8.28 - 99.41
        • Shares outstanding share-outstanding 110,218,000
        • 10 Years Aggregate:

          CFO: $-270.79 Mln

          EBITDA: $-346.12 Mln

          Net Profit: $-375.21 Mln

        About The Company

        • IPO Date 29-Apr-2015
        • President, CEO & Director Dr. Brian Lian Ph.D.
        • Chief Financial Officer Mr. Gregory S. Zante
        • Listing key-listing NASDAQ: VKTX
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://www.vikingtherapeutics.com
        • Business

          Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype...  selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.  Read more

        share-fund-plan-icon